Description
Gaining access to financial services in the US is proving difficult for CBD companies, despite hemp being legalised at the federal level. The lack of a clear regulatory framework for CBD products has meant that many financial institutions place higher costs on CBD companies. This report addresses the reasons why the problem persists and what could be done to address it.